Piller V, Piller F, Klier F G, Fukuda M
La Jolla Cancer Research Foundation, Cancer Research Center.
Eur J Biochem. 1989 Jul 15;183(1):123-35. doi: 10.1111/j.1432-1033.1989.tb14904.x.
The O-glycosylation of leukosialin, a major sialoglycoprotein found on leukocytes, has been studied in the human erythroleukemic cell line K562. The appearance of its O-linked chains has been followed in pulse-chase experiments with [35S]methionine by immunoprecipitation with an anti-peptide antiserum as well as with a lectin from Salvia sclarea seeds (SSA) specific for GalNAc-Ser/Thr and the peanut (Arachis hypogaea) agglutinin (PNA) which recognizes Gal beta 1----3GalNAc-Ser/Thr structures. An O-glycan-free precursor was converted into the fully O-glycosylated mature form within the 10-min labeling period and no intermediates carrying only GalNAc-Ser/Thr structures could be detected. The ionophore monensin was used in order to slow down intracellular traffic and thus O-glycan synthesis. The drug partly inhibited the transport from rough endoplasmic reticulum (RER) to the Golgi and also the cell-surface expression of leukosialin. It was found to have a marked effect on the synthesis of O-linked carbohydrate structures of leukosialin since the amount of O-glycans containing only GalNAc or NeuNAc alpha 2----6GalNAc was significantly increased after monensin treatment. Under these conditions the biosynthesis of the N-glycan on leukosialin was completely arrested in an endoglycosidase-H-sensitive step of processing, whereas the O-glycans already contained galactose and sialic acid although at a reduced level. On the other hand, the small amounts of leukosialin expressed on the cell surface of monensin-treated cells carried the same glycans as those remaining blocked inside the cell. In addition, immunocytochemical studies using SSA and PNA on untreated K562 cells suggested the absence of detectable amounts of GalNAc-Ser/Thr-bearing glycoproteins in the RER as well as in the Golgi. In contrast Gal beta 1----3GalNAc structures could be detected on intracellular membranes which were tentatively identified as the cis-Golgi. Together these results lead us to the following conclusions: N-glycan transfer occurs in the RER before the initiation of O-glycans which takes place at the entrance of the protein into the Golgi; further elongation of O-glycans with galactose and sialic acid follows very rapidly, probably before the final processing of N-glycans to complex-type structures.
白细胞表面主要的唾液酸糖蛋白——白细胞唾液酸蛋白的O-糖基化,已在人红白血病细胞系K562中进行了研究。在脉冲追踪实验中,用[35S]甲硫氨酸标记,并用抗肽抗血清以及来自鼠尾草种子的凝集素(SSA,对GalNAc-Ser/Thr具有特异性)和花生凝集素(PNA,可识别Galβ1----3GalNAc-Ser/Thr结构)进行免疫沉淀,追踪其O-连接链的出现情况。一种无O-聚糖的前体在10分钟的标记期内转化为完全O-糖基化的成熟形式,未检测到仅携带GalNAc-Ser/Thr结构的中间体。使用离子载体莫能菌素以减缓细胞内运输,从而减缓O-聚糖的合成。该药物部分抑制了从粗面内质网(RER)到高尔基体的转运以及白细胞唾液酸蛋白的细胞表面表达。发现它对白细胞唾液酸蛋白的O-连接碳水化合物结构的合成有显著影响,因为在莫能菌素处理后,仅含有GalNAc或NeuNAcα2----6GalNAc的O-聚糖的量显著增加。在这些条件下,白细胞唾液酸蛋白上N-聚糖的生物合成在加工的内切糖苷酶-H敏感步骤中完全停止,而O-聚糖已经含有半乳糖和唾液酸,尽管含量有所降低。另一方面,在莫能菌素处理的细胞表面表达的少量白细胞唾液酸蛋白携带的聚糖与留在细胞内受阻的聚糖相同。此外,对未处理的K562细胞使用SSA和PNA进行免疫细胞化学研究表明,在RER以及高尔基体中未检测到可检测量的携带GalNAc-Ser/Thr的糖蛋白。相反,在暂定为顺式高尔基体的细胞内膜上可检测到Galβ1----3GalNAc结构。这些结果共同使我们得出以下结论:N-聚糖转移发生在RER中且在O-聚糖起始之前,O-聚糖起始发生在蛋白质进入高尔基体时;O-聚糖用半乳糖和唾液酸的进一步延伸非常迅速,可能在N-聚糖最终加工成复杂型结构之前。